Company Filing History:
5 out of 233 
2 out of 1,440 
Years Active: 2016-2017
Title: The Innovations of Andrew Crofton
Introduction
Andrew Crofton is an accomplished inventor based in Loma Linda, California. He has made significant contributions to the field of biomedical applications, particularly in the identification and treatment of neurological conditions. With a total of three patents to his name, Crofton continues to push the boundaries of innovation in his area of expertise.
Latest Patents
One of Crofton's latest patents is focused on the Dynactin subunit p62 biomarker for neurological conditions. This patent discloses methods and kits for identifying neurological conditions in patients by determining the level of expression of dynactin subunit p62. The neurological conditions addressed may include Alzheimer's Disease (AD) without cerebral amyloid angiopathy (CAA). Another notable patent involves the composition, preparation, and use of chitosan shards for biomedical applications. This patent describes a thin chitosan-based material that can be utilized in various biomedical applications. The chitosan is treated in a nitrogen field by applying energy to ionize nitrogen in and around the chitosan material. This innovative approach allows for multiple treatments, such as irradiating under nitrogen using γ-irradiation or treating under a nitrogen plasma.
Career Highlights
Throughout his career, Andrew Crofton has worked with prestigious institutions, including Loma Linda University and North Carolina State University. His work has been instrumental in advancing research and development in the biomedical field.
Collaborations
Crofton has collaborated with notable colleagues, including Wolff M Kirsch and Samuel Mack Hudson. These partnerships have contributed to the success of his innovative projects and patents.
Conclusion
Andrew Crofton exemplifies the spirit of innovation in the biomedical field. His patents and collaborations reflect his commitment to improving the understanding and treatment of neurological conditions. His work continues to inspire future advancements in medical technology.